For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Duration of response

First-line Tafinlar + Mekinist demonstrated durable responses, with a median duration of response of 39.6 months in patients who achieved a CR in the COMBI-v trial1

Tafinlar® (dabrafenib) + Mekinist® (trametinib) duration of response

  • The majority of patients (53%) who achieved a CR on first-line Tafinlar + Mekinist remained in CR after a median follow-up of 23 months in the COMBI-v study1

In the 2 phase 3 studies, Tafinlar + Mekinist demonstrated durable responses, with median durations of response ranging from 12.9 to 13.8 months1,2

Duration of response phase 3 studies Tafinlar® (dabrafenib) + Mekinist® (trametinib)

  • In COMBI-v, the median duration of response with Tafinlar + Mekinist was 13.8 months compared with 7.9 months with vemurafenib1
  • In COMBI-d, the median duration of response with Tafinlar + Mekinist was 12.9 months compared with 10.6 months with Tafinlar monotherapy2

CR, complete response.

References: 1. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Presented at: European Society for Medical Oncology; October 7-11, 2016; Copenhagen, Denmark. 2. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.